Please assess the completion status of the following clinical trial:

Trial Title: Ezetimibe/Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has not taken common statins or ezetimibe within 6 weeks of study screening or patient is currently taking a daily dose of the following statins for 6 weeks prior to study screening: simvastatin, atorvastatin, pravastatin, fluvastatin, ezetimibe, lovastatin, or ezetimibe + fluvastatin~* Patient is willing to go on a cholesterol and glucose lowering diet for the duration of the study~* Patient is willing to remain abstinent or use birth control for the duration of the study~* Patient has Diabetes Mellitus with cardiovascular disease~Exclusion Criteria:~* Patient has sensitivity to certain common statin drugs~* Patient is Asian and would not be able to start taking the higher doses of rosuvastatin necessary for the study design~* Patient consumes more than 2 alcoholic drinks per day~* Patient is pregnant or breast-feeding~* Patient has been treated with other investigational drugs within 30 days of first visit~* Patient is currently on prohibited doses of the following statin drugs: rosuvastatin, simvastatin, atorvastatin, and pravastatin~* Patient has congestive heart failure~* Patient has uncontrolled high blood pressure~* Patient has kidney disease~* Patient has uncontrolled endocrine or metabolic disease which are known to possibly increase blood lipoproteins~* Patient has diabetes mellitus that is not well controlled~* Patient is human immunodeficiency virus (HIV) positive~* Patient is currently taking medications that inhibit Cytochrome P450 3A4 (CYP3A4)~* Patient is currently taking therapies that would increase the risk of muscle weakness~* Patient has been taking certain over- the-counter lipid-lowering agents within 6 weeks prior to visit 1~* Patient is currently taking psyllium or other fiber-based laxatives

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Ezetimibe/simvastatin (Type: EXPERIMENTAL): None
- Doubling statin dose (Type: ACTIVE_COMPARATOR): None
- Rosuvastatin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).